PE20130155A1 - Derivados de ariletinilo - Google Patents
Derivados de ariletiniloInfo
- Publication number
- PE20130155A1 PE20130155A1 PE2012002013A PE2012002013A PE20130155A1 PE 20130155 A1 PE20130155 A1 PE 20130155A1 PE 2012002013 A PE2012002013 A PE 2012002013A PE 2012002013 A PE2012002013 A PE 2012002013A PE 20130155 A1 PE20130155 A1 PE 20130155A1
- Authority
- PE
- Peru
- Prior art keywords
- alcoxy
- lower alkyl
- cycloalkyl
- independently
- carbon atom
- Prior art date
Links
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 150000001721 carbon Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 101150087728 Grm5 gene Proteins 0.000 abstract 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA I DONDE: U ES =N- O =C(R5), V ES -CH= O -N=, W ES =CH O =N-, CON LA CONDICION DE QUE UNO SOLAMENTE PUEDA SER N; R5 ES H, METILO O HALOGENO; Y ES -O-, -CH2O-, -CH2S(O)2, ENTRE OTROS; R1 ES FENILO O HETEROARILO OPCIONALMENTE SUSTITUIDOS POR HALOGENO, ALQUILO INFERIOR Y ALCOXI INFERIOR; R2/R2´ JUNTO CON EL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN CICLOALQUILO C3-C6 O UN ANILLO QUE CONTIENE -CH2OCH2-, O SON INDEPENDIENTEMENTE H, ALQUILO INFERIOR, HIDROXI, ALCOXI INFERIOR, ENTRE OTROS; m ES 0, 1, O 2; CUANDO m ES 1: R3/R3´ JUNTO CON EL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN CICLOALQUILO C3-C6, O SON INDEPENDIENTEMENTE H, ALQUILO INFERIOR, CH2-ALCOXI INFERIOR; n ES 0 O 1; CUANDO n ES 1: R4/R4´ JUNTO CON EL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN CICLOALQUILO C3-C6, O SON INDEPENDIENTEMENTE H, ALQUILO INFERIOR, CH2-ALCOXI INFERIOR. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE OBTENCION. DICHOS COMPUESTOS SON MODULADORES ALOSTERICOS DE MGLUR5, SIENDO UTILES PARA EL TRATAMIENTO DE ESQUIZOFRENIA, AUTISMO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10159754 | 2010-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130155A1 true PE20130155A1 (es) | 2013-02-21 |
Family
ID=44140916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002013A PE20130155A1 (es) | 2010-04-13 | 2011-04-11 | Derivados de ariletinilo |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US8420661B2 (es) |
| EP (1) | EP2558457B1 (es) |
| JP (1) | JP5559418B2 (es) |
| KR (1) | KR101431367B1 (es) |
| CN (1) | CN102947289B (es) |
| AR (1) | AR080878A1 (es) |
| AU (1) | AU2011240131B2 (es) |
| BR (1) | BR112012026004A2 (es) |
| CA (1) | CA2786216C (es) |
| CL (1) | CL2012002771A1 (es) |
| CR (1) | CR20120480A (es) |
| CY (1) | CY1117441T1 (es) |
| DK (1) | DK2558457T3 (es) |
| EC (1) | ECSP12012212A (es) |
| ES (1) | ES2565761T3 (es) |
| HR (1) | HRP20160617T1 (es) |
| HU (1) | HUE027105T2 (es) |
| IL (1) | IL220982A (es) |
| MA (1) | MA34078B1 (es) |
| MX (1) | MX2012011841A (es) |
| MY (1) | MY160490A (es) |
| NZ (1) | NZ601024A (es) |
| PE (1) | PE20130155A1 (es) |
| PH (1) | PH12012501773A1 (es) |
| PL (1) | PL2558457T3 (es) |
| RS (1) | RS54708B1 (es) |
| RU (1) | RU2573560C2 (es) |
| SG (1) | SG183974A1 (es) |
| SI (1) | SI2558457T1 (es) |
| TW (1) | TWI445706B (es) |
| UA (1) | UA107491C2 (es) |
| WO (1) | WO2011128279A1 (es) |
| ZA (1) | ZA201207285B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010104818A1 (en) * | 2009-03-09 | 2010-09-16 | Bristol-Myers Squibb Company | Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| PL2702051T3 (pl) * | 2011-04-26 | 2015-08-31 | Hoffmann La Roche | Pochodne etynylu jako pozytywne allosteryczne modulatory mglur5 |
| US20130123254A1 (en) * | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| EA026593B1 (ru) * | 2012-07-17 | 2017-04-28 | Ф. Хоффманн-Ля Рош Аг | Арилэтиниловые производные |
| UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
| JP6027251B2 (ja) * | 2012-09-27 | 2016-11-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | アリールエチニル誘導体 |
| UA116023C2 (uk) | 2013-07-08 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як антагоністи метаботропного глутаматного рецептора |
| EP3049409B1 (en) * | 2013-09-25 | 2017-05-03 | F. Hoffmann-La Roche AG | Ethynyl derivatives |
| TWI649310B (zh) * | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
| MA39305A3 (fr) * | 2014-02-25 | 2018-05-31 | Hoffmann La Roche | Dérivés d'éthynyle |
| CN107207481B (zh) * | 2015-03-19 | 2020-03-03 | 豪夫迈·罗氏有限公司 | 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2,4-二酮衍生物 |
| LT3303316T (lt) * | 2015-06-03 | 2020-05-11 | F. Hoffmann-La Roche Ag | Etinilo dariniai |
| ES2733468T3 (es) * | 2015-07-15 | 2019-11-29 | Hoffmann La Roche | Derivados de etinilo como moduladores de los receptores metabotrópicos de glutamato |
| AR105556A1 (es) * | 2015-08-03 | 2017-10-18 | Hoffmann La Roche | Derivados de etinilo |
| CN106632243B (zh) * | 2015-10-28 | 2019-03-15 | 华领医药技术（上海）有限公司 | 吡咯烷衍生物 |
| WO2018015235A1 (en) | 2016-07-18 | 2018-01-25 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
| CN108947883A (zh) * | 2017-05-25 | 2018-12-07 | 北京万全德众医药生物技术有限公司 | 布瓦西坦的制备 |
| JP7191045B2 (ja) * | 2017-06-02 | 2022-12-16 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 化合物 |
| WO2018220149A1 (en) | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Compounds |
| SG11202011818YA (en) | 2018-06-29 | 2020-12-30 | Hoffmann La Roche | Compounds |
| MA53220A (fr) * | 2018-08-13 | 2021-11-17 | Hoffmann La Roche | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase |
| ES2986417T3 (es) | 2018-08-13 | 2024-11-11 | Hoffmann La Roche | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| ES2955037T3 (es) | 2018-11-22 | 2023-11-28 | Hoffmann La Roche | Nuevos compuestos heterocíclicos |
| CN113993591A (zh) | 2019-06-21 | 2022-01-28 | 豪夫迈·罗氏有限公司 | 新egfr抑制剂 |
| CN114008049B (zh) | 2019-06-21 | 2024-07-05 | 豪夫迈·罗氏有限公司 | 用于癌症治疗的egfr抑制剂 |
| EP4028403B1 (en) | 2019-09-12 | 2023-11-22 | F. Hoffmann-La Roche AG | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| CN114018880B (zh) * | 2021-10-22 | 2024-02-27 | 杭州食疗晶元生物科技有限公司 | 基于内源活性中间体对纯净水和天然矿泉水的鉴别方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI90869C (fi) * | 1986-11-14 | 1994-04-11 | Tanabe Seiyaku Co | Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi |
| GB9510744D0 (en) | 1995-05-26 | 1995-07-19 | Zeneca Ltd | Chemical process |
| DE19546462A1 (de) * | 1995-12-13 | 1997-06-19 | Bayer Ag | Diarylacetylenketone |
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| EP1214303A1 (en) | 1999-08-31 | 2002-06-19 | Merck & Co., Inc. | Heterocyclic compounds and methods of use thereof |
| ES2252063T3 (es) * | 1999-09-28 | 2006-05-16 | Eisai Co., Ltd. | Compuesto de quinuclidina y medicamento que comprende el compuesto como principio activo. |
| US7112593B2 (en) * | 2001-03-27 | 2006-09-26 | Eisai Co., Ltd. | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient |
| CL2004000847A1 (es) * | 2003-04-23 | 2005-03-11 | Schering Corp | Compuestos derivados de 2-alquinil o 2-alquenil-5amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-]pirimidina; composicion farmaceutica, y uso en el tratamiento de enfermedades del sistema nervioso central o un accidente cerebrovascular tal como depresion, |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| US7915424B2 (en) * | 2004-03-22 | 2011-03-29 | Eli Lilly And Company | Pyridyl derivatives and their use as mGlu5 antagonists |
| JPWO2005108370A1 (ja) * | 2004-04-16 | 2008-03-21 | 味の素株式会社 | ベンゼン化合物 |
| US7879882B2 (en) * | 2004-10-07 | 2011-02-01 | Merck Sharp & Dohme Corp. | Thiazolyl mglur5 antagonists and methods for their use |
| WO2006048771A1 (en) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| SG185285A1 (en) * | 2007-06-03 | 2012-11-29 | Univ Vanderbilt | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| US8853392B2 (en) | 2007-06-03 | 2014-10-07 | Vanderbilt University | Benzamide mGluR5 positive allosteric modulators and methods of making and using same |
| WO2010063487A1 (en) * | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| CN101544892B (zh) * | 2009-05-07 | 2012-10-03 | 石家庄诚志永华显示材料有限公司 | 一种合成二芳基乙炔类单体液晶的方法 |
| TW201116532A (en) * | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| US8389536B2 (en) * | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
-
2011
- 2011-04-05 US US13/066,044 patent/US8420661B2/en active Active
- 2011-04-11 HR HRP20160617TT patent/HRP20160617T1/hr unknown
- 2011-04-11 MY MYPI2012004559A patent/MY160490A/en unknown
- 2011-04-11 AR ARP110101210A patent/AR080878A1/es unknown
- 2011-04-11 RU RU2012145237/04A patent/RU2573560C2/ru not_active IP Right Cessation
- 2011-04-11 SI SI201130777A patent/SI2558457T1/sl unknown
- 2011-04-11 PE PE2012002013A patent/PE20130155A1/es active IP Right Grant
- 2011-04-11 RS RS20160259A patent/RS54708B1/sr unknown
- 2011-04-11 PL PL11713288.6T patent/PL2558457T3/pl unknown
- 2011-04-11 WO PCT/EP2011/055585 patent/WO2011128279A1/en not_active Ceased
- 2011-04-11 PH PH1/2012/501773A patent/PH12012501773A1/en unknown
- 2011-04-11 BR BR112012026004A patent/BR112012026004A2/pt not_active Application Discontinuation
- 2011-04-11 NZ NZ601024A patent/NZ601024A/en not_active IP Right Cessation
- 2011-04-11 EP EP11713288.6A patent/EP2558457B1/en active Active
- 2011-04-11 CA CA2786216A patent/CA2786216C/en not_active Expired - Fee Related
- 2011-04-11 ES ES11713288.6T patent/ES2565761T3/es active Active
- 2011-04-11 MX MX2012011841A patent/MX2012011841A/es active IP Right Grant
- 2011-04-11 HU HUE11713288A patent/HUE027105T2/en unknown
- 2011-04-11 KR KR1020127029579A patent/KR101431367B1/ko not_active Expired - Fee Related
- 2011-04-11 JP JP2013504215A patent/JP5559418B2/ja not_active Expired - Fee Related
- 2011-04-11 MA MA35234A patent/MA34078B1/fr unknown
- 2011-04-11 DK DK11713288.6T patent/DK2558457T3/en active
- 2011-04-11 TW TW100112500A patent/TWI445706B/zh not_active IP Right Cessation
- 2011-04-11 CN CN201180015120.3A patent/CN102947289B/zh not_active Expired - Fee Related
- 2011-04-11 SG SG2012066759A patent/SG183974A1/en unknown
- 2011-04-11 AU AU2011240131A patent/AU2011240131B2/en not_active Ceased
- 2011-11-04 UA UAA201212800A patent/UA107491C2/uk unknown
-
2012
- 2012-07-16 IL IL220982A patent/IL220982A/en active IP Right Grant
- 2012-09-24 CR CR20120480A patent/CR20120480A/es unknown
- 2012-09-28 ZA ZA2012/07285A patent/ZA201207285B/en unknown
- 2012-10-02 EC ECSP12012212 patent/ECSP12012212A/es unknown
- 2012-10-03 CL CL2012002771A patent/CL2012002771A1/es unknown
-
2013
- 2013-02-28 US US13/779,782 patent/US8513273B2/en active Active
- 2013-06-10 US US13/914,336 patent/US8618296B2/en not_active Expired - Fee Related
- 2013-11-20 US US14/085,064 patent/US9315498B2/en active Active
-
2016
- 2016-04-27 CY CY20161100357T patent/CY1117441T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130155A1 (es) | Derivados de ariletinilo | |
| AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
| PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
| PE20141556A1 (es) | Derivados de etinilo como moduladores alostericos de mglur5 | |
| AR079334A1 (es) | Derivados de oxazin amino | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| PE20142461A1 (es) | Moduladores del receptor de estrogeno y sus usos | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| PE20130279A1 (es) | Compuestos heteroarilo nitrogenados | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
| ES2422299T3 (es) | Indoles (4,5-dihidro) indoles tricíclicos | |
| PE20141169A1 (es) | Derivados de etinilo | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| AR073565A1 (es) | Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| PE20141168A1 (es) | Derivados de pirazolidin-3-ona | |
| AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
| ES2568909T3 (es) | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 | |
| PE20141579A1 (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
| PE20140984A1 (es) | 5 -(fenil / piridinil-etinilo)-2-piridina / 2-pirimidina carboxamidas como moduladores de mglur5 | |
| MY153042A (en) | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | |
| PE20180316A1 (es) | Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |